First Time Loading...
A

Akoya Biosciences Inc
NASDAQ:AKYA

Watchlist Manager
Akoya Biosciences Inc
NASDAQ:AKYA
Watchlist
Price: 4.04 USD 1.25% Market Closed
Updated: May 5, 2024
Section:
 

Wall Street
Price Targets

AKYA Price Targets Summary
Akoya Biosciences Inc

Wall Street analysts forecast AKYA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AKYA is 9.01 USD with a low forecast of 7.07 USD and a high forecast of 11.55 USD.

AKYA Lowest Forecast
Wall Street Target
7.07 USD
75% Upside
AKYA Average Forecast
Wall Street Target
9.01 USD
123% Upside
AKYA Highest Forecast
Wall Street Target
11.55 USD
186% Upside
Lowest
Price Target
7.07 USD
75% Upside
Average
Price Target
9.01 USD
123% Upside
Highest
Price Target
11.55 USD
186% Upside
Akoya Biosciences Inc Competitors:
Price Targets
G
688046
GemPharmatech Co Ltd
83% Upside
DIVISLAB
Divi's Laboratories Ltd
14% Downside
S
1SXP
SCHOTT Pharma AG & Co KgaA
4% Upside
QGEN
Qiagen NV
21% Upside
G
688046
GemPharmatech Co Ltd
83% Upside
DIVISLAB
Divi's Laboratories Ltd
14% Downside
S
1SXP
SCHOTT Pharma AG & Co KgaA
4% Upside
QGEN
Qiagen NV
21% Upside
GSS
Genetic Signatures Ltd
9% Upside
WST
West Pharmaceutical Services Inc
13% Upside
O
ORPH
Open Orphan PLC
199% Upside
PPGN
PolyPeptide Group AG
25% Downside

Revenue
Forecast

Revenue Estimate
Akoya Biosciences Inc

For the last 3 years the compound annual growth rate for Akoya Biosciences Inc's revenue is 32%. The projected CAGR for the next 3 years is 20%.

32%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Akoya Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Akoya Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-22%
Average Miss
What are analyst estimates?

See Also

Summary
AKYA intrinsic value, competitors valuation, and company profile.
DCF Valuation
AKYA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AKYA stock valuation using valuation multiples.
Wall Street Estimates
AKYA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AKYA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AKYA's stock price target?
Price Target
9.01 USD

According to Wall Street analysts, the average 1-year price target for AKYA is 9.01 USD with a low forecast of 7.07 USD and a high forecast of 11.55 USD.

What is Akoya Biosciences Inc's Revenue forecast?
Projected CAGR
20%

For the last 3 years the compound annual growth rate for Akoya Biosciences Inc's revenue is 32%. The projected CAGR for the next 3 years is 20%.

ALPHA SPREAD
Join more than 134,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.